← Back to Clinical Trials
Recruiting NCT06830993

NCT06830993 Physical Activity Prescription Program for Hemodialysis Patients

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT06830993
Status Recruiting
Phase
Sponsor University of Arizona
Condition Hemodialysis
Study Type INTERVENTIONAL
Enrollment 40 participants
Start Date 2025-07-01
Primary Completion 2026-08

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age N/A
Study Type INTERVENTIONAL
Interventions
"Move More" Personalized Exercise ProgramIntradialytic Exercise Program

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 40 participants in total. It began in 2025-07-01 with a primary completion date of 2026-08.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

The goal of this clinical trial is to compare the efficacy of a standard intradialytic exercise program (control group) to an individualized, patient-centered, "Move-More" physical activity intervention (intervention group) in hemodialysis (HD) patients. Exercise programs often fail to yield robust benefits for many HD patients, in part because the type and volume of exercise prescribed is inappropriate for a variety of reasons, and the benefits from these studies are often disappointing, as they are characterized by poor adherence, high dropout rates, and modest effects on physical function, body composition, cardiovascular disease risk, and other outcomes related to quality of life (QOL). To address this, the investigators have designed a novel physical activity intervention "Move More" that is designed to overcome many of the barriers to increasing physical activity in this population. This study aims to compare the efficacy of a standard intradialytic exercise program (control group) to an individualized, patient-centered, "Move-More" physical activity intervention (intervention group) in HD patients. The investigators primary hypothesis is that patients randomized to the Move More intervention will increase their physical activity levels more than those in the intradialytic exercise group. The main question it aims to answer is: • Does "Move More" increase the physical activity levels (minutes) measured through weekly minutes of physical activity and the LoPAQ questionnaire more than those in the standard intradialytic exercise program? For secondary outcomes this study aims to answer the following: * Does "Move More" improve the physical function of hemodialysis patients assessed by the short physical performance battery (SPBB) more than those in the standard intradialytic exercise program? * Does "Move More" decrease fatigue assess by the SONG-HD survey more than those in the standard intradialytic exercise program? * Does "Move More" decrease symptoms of depression assessed by PROMIS Depression Short Form 8a more than those in the standard intradialytic exercise program? * Does "Move More" increase the amount of exercise measured through a point system more than those in the standard intradialytic exercise program? * Does "Move More" improve blood pressure (BP) more than those in the standard intradialytic exercise program?

Eligibility Criteria

Inclusion Criteria: * ≥ 18 years old (no upper age limit); * Chronic hemodialysis for ≥ 3 months; * No planned or expected change in dialysis modality, elective surgery, or relocation during the study period (24 weeks); * Able to communicate in English or Spanish and provide written informed consent; * Assessed to be safe and able to exercise by the Hemodialysis unit nephrologist Exclusion Criteria: * Physical Activity: patients undergoing \>150 minutes/week of prescribed PA at baseline will be excluded from the study. * Physician Clearance: Patients who do not receive physician clearance to participate in the study will be excluded from the study.

Contact & Investigator

Central Contact

Kenneth R Wilud, PhD

✉ kwilund@arizona.edu

📞 520.621.3096

Principal Investigator

Kenneth R Wilud, PhD

PRINCIPAL INVESTIGATOR

University of Arizona

Frequently Asked Questions

Who can join the NCT06830993 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, studying Hemodialysis. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT06830993 currently recruiting?

Yes, NCT06830993 is actively recruiting participants. Contact the research team at kwilund@arizona.edu for enrollment information.

Where is the NCT06830993 trial being conducted?

This trial is being conducted at Tucson, United States.

Who is sponsoring the NCT06830993 clinical trial?

NCT06830993 is sponsored by University of Arizona. The principal investigator is Kenneth R Wilud, PhD at University of Arizona. The trial plans to enroll 40 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: September 2026  ·  Data Methodology